CHST4: A Drug Target / Disease Biomarker (G10164)

Target Name: CHST4

NCBI ID: G10164

CHST4

CHST4: A Drug Target / Disease Biomarker

CHST4, also known as human chorionic gonadotropin (hCG), is a protein produced by the placenta during pregnancy. It is a key regulator of pregnancy, and its levels have been linked to a range of important health outcomes.

CHST4 is a glycoprotein, which means it consists of a protein that is made up of multiple polypeptides. It is expressed in the placenta, and it plays a vital role in the development and maintenance of the pregnancy.

During pregnancy, CHST4 is produced by the placenta in response to the presence of human chorionic gonadotropin (hCG), which is produced by the placenta itself. HCG is a hormone that is responsible for maintaining pregnancy, and it is produced by the placenta in response to the pregnancy-specific antigens that it encounters.

CHST4 is a key regulator of the pregnancy-specific antigens, which are molecules that are produced by the placenta in response to the pregnancy. These antigens include the placenta-specific antigens, which are molecules that are produced by the placenta specifically for use by the fetus, and the pregnancy-specific antigens, which are molecules that are produced by the placenta specifically for use by the placenta itself.

CHST4 is also involved in the regulation of the pregnancy-specific antigens. It does this by interacting with a protein called PDGF, which is produced by the placenta. This interaction between CHST4 and PDGF allows CHST4 to regulate the production of the pregnancy-specific antigens, which is important for the proper development and maintenance of the pregnancy.

In addition to its role in the regulation of pregnancy-specific antigens, CHST4 is also involved in the development and maintenance of the placenta itself. It does this by interacting with another protein called ICAM-1, which is produced by the endothelial cells of the placenta. This interaction between CHST4 and ICAM-1 allows CHST4 to regulate the growth and development of the placenta, which is important for the proper functioning of the pregnancy.

CHST4 is also involved in the regulation of the production of other proteins during pregnancy. It does this by interacting with a protein called TGF-β, which is produced by the placenta. This interaction between CHST4 and TGF-β allows CHST4 to regulate the production of other proteins during pregnancy, which is important for the proper development and maintenance of the pregnancy.

CHST4 is also involved in the regulation of the production of other proteins during pregnancy. It does this by interacting with a protein called NF-kappa-B, which is produced by the placenta. This interaction between CHST4 and NF-kappa-B allows CHST4 to regulate the production of other proteins during pregnancy, which is important for the proper development and maintenance of the pregnancy.

In conclusion, CHST4 is a protein that is produced by the placenta during pregnancy. It is a key regulator of pregnancy, and its levels have been linked to a range of important health outcomes.

CHST4 is involved in the regulation of pregnancy-specific antigens, which are molecules that are produced by the placenta specifically for use by the fetus. It is also involved in the regulation of the growth and development of the placenta, which is important for the proper functioning of the pregnancy.

CHST4 is also involved in the regulation of the production of other proteins during pregnancy. It does this by interacting with a protein called PDGF

Protein Name: Carbohydrate Sulfotransferase 4

Functions: Sulfotransferase involved in SELL/L-selectin ligand biosynthesis pathway. Catalyzes the transfer of the sulfate group from 3'-phospho-5'-adenylyl sulfate (PAPS) onto the hydroxyl group at C-6 position of the non-reducing N-acetylglucosamine (GlcNAc) residue within O-linked mucin-type glycans. Contributes to generate sialyl 6-sulfo Lewis X determinant (also known as MECA-79 epitope) for SELL recognition, a prerequisite for continuous lymphocyte homing into peripheral lymph nodes and antigen immune surveillance (PubMed:11439191, PubMed:12107080, PubMed:10330415, PubMed:11726653). Transfers the sulfate group primarily on core 2 GlcNAcbeta1-6(Galbeta1-3)GalNAcalphaSer/Thr and extended core 1 GlcNAcbeta1-3Galbeta1-3GalNAcalphaSer/Thr based O-linked glycans on CD34 and GLYCAM1 peripheral node addressins (PNAds) expressed on the lumenal side of high endothelial venules (HEVs) (PubMed:11439191). The recognition of PNAds by SELL initiates a multistep process comprising tethering and rolling of blood lymphocytes on HEVs against the blood flow, followed by chemokine signaling, integrin-mediated lymphocyte adhesion onto endothelial cells and lymphocyte transendothelial migration. Modulates rolling velocity and differential T and B lymphocyte recruitment into peripheral lymph nodes, with a major role in B lymphocyte homing. Might be redundant in sulfation of MADCAM1 and lymphocyte trafficking to mesenteric lymph nodes (By similarity). Can also sulfonate core 3 GlcNAcbeta1-3GalNAc-R based glycans as well as GlcNAcbeta1-3Galbeta1-Glc, GlcNAcbeta1-6ManOMe and GlcNAcbeta1-2Man oligosaccharides, which might be ectopically expressed during tumorigenesis (PubMed:12107080, PubMed:11439191, PubMed:11726653)

The "CHST4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHST4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets